What it's for (Indications)
- Betamethasone dipropionate, topical, combined with gentamicin, is indicated for the treatment of inflammatory dermatoses that are complicated by, or at high risk of developing, secondary bacterial infections caused by gentamicin-susceptible organisms.
- This includes conditions such as eczema, atopic dermatitis, seborrheic dermatitis, and psoriasis where bacterial colonization or active infection is present or highly anticipated.
- The potent corticosteroid component effectively reduces inflammation, pruritus, and erythema, while the antibiotic addresses the bacterial component.
- It is generally intended for short-term use, typically not exceeding two weeks, to manage acute exacerbations and mitigate the risks associated with prolonged use of both a potent corticosteroid and an aminoglycoside antibiotic.
- Careful diagnosis and identification of the causative organisms are crucial before initiating therapy to ensure appropriate antimicrobial stewardship and patient safety.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for betamethasone dipropionate, topical, combined with gentamicin, involves applying a thin layer to the affected skin areas typically twice daily. The duration of treatment should be limited, generally not exceeding two weeks, and should be re-evaluated by a healthcare professional if no improvement is seen, or if the condition worsens. For pediatric patients, the duration of treatment should be even shorter, and the smallest effective amount should be used, due to the increased risk of systemic absorption and HPA axis suppression. Occlusive dressings are generally not recommended with this product as they can significantly increase systemic absorption of both components, thereby augmenting the risk of side effects. The treatment should be discontinued once the infection is controlled and the inflammatory symptoms have subsided to minimize the development of antimicrobial resistance and corticosteroid-induced adverse effects. |
Safety & Warnings
Common Side Effects
- Adverse effects associated with betamethasone dipropionate and gentamicin topical combination therapy can be localized or, rarely, systemic, particularly with prolonged use, application to large surface areas, or under occlusive dressings.
- Local reactions may include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
- Systemic effects of the corticosteroid, although less common with topical application, can manifest as reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.
- Children are particularly susceptible to HPA axis suppression due to a higher skin surface area to body weight ratio.
- Gentamicin, when absorbed systemically, carries risks of ototoxicity and nephrotoxicity, though these are exceedingly rare with topical application on intact skin.
- However, absorption can be increased through damaged skin, large surface areas, or prolonged use.
- Hypersensitivity reactions to either component may also occur.
- Prolonged use can also lead to the development of bacterial resistance to gentamicin, reducing its efficacy for future infections.
Serious Warnings
- Black Box Warning: **Serious Warnings Regarding Systemic Absorption and Resistance:** While betamethasone dipropionate with gentamicin topical does not carry a formal FDA Black Box Warning, it is imperative for healthcare providers and patients to be aware of significant risks associated with its use. Prolonged application, use on large surface areas, application under occlusive dressings, or use on damaged skin can lead to substantial systemic absorption of both betamethasone and gentamicin. This absorption significantly increases the risk of hypothalamic-pituitary-adrenal (HPA) axis suppression, which can manifest as Cushing's syndrome, hyperglycemia, and growth retardation in pediatric patients. In rare instances, systemic absorption of gentamicin can result in ototoxicity and nephrotoxicity, particularly in individuals with compromised renal function or pre-existing hearing impairments. Furthermore, the indiscriminate or prolonged use of topical gentamicin contributes to the development of bacterial resistance, rendering the antibiotic ineffective against future infections. Therefore, this medication should be used for the shortest duration necessary to control the infection and inflammation, generally not exceeding two weeks, and under strict medical supervision, especially in pediatric populations, to mitigate these serious risks.
- Betamethasone dipropionate with gentamicin topical is for external use only and should not be used in the eyes, on mucous membranes, or internally.
- Prolonged use or application to large body surface areas, particularly under occlusive dressings, may result in significant systemic absorption of both the corticosteroid and the aminoglycoside antibiotic.
- This can lead to HPA axis suppression, Cushing's syndrome, hyperglycemia, and, in susceptible individuals or with extensive absorption, gentamicin-induced ototoxicity and nephrotoxicity.
- Pediatric patients are more susceptible to systemic toxicity due to a higher ratio of skin surface area to body weight.
- Treatment should be limited to the shortest duration necessary, usually not more than two weeks, to minimize these risks and prevent the development of bacterial resistance to gentamicin.
- The presence of a corticosteroid can mask the clinical signs of infection, and prolonged use can lead to secondary infections, including fungal or viral infections, requiring appropriate antifungal or antiviral therapy.
- Discontinue treatment if irritation, sensitization, or superinfection occurs.
- Not recommended for conditions such as rosacea, perioral dermatitis, or acne vulgaris, as corticosteroids can exacerbate these conditions.
- Use during pregnancy or lactation should only occur if the potential benefit justifies the potential risk to the fetus or infant.
How it Works (Mechanism of Action)
This topical preparation combines the anti-inflammatory and antipruritic actions of a potent corticosteroid with the bactericidal activity of an aminoglycoside antibiotic. Betamethasone dipropionate, a synthetic corticosteroid, exerts its therapeutic effects by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid, from membrane phospholipids. This leads to a reduction in the inflammatory cascade, vasoconstriction, and decreased permeability of capillaries, thereby alleviating symptoms like redness, swelling, and itching. Gentamicin, an aminoglycoside antibiotic, binds irreversibly to the 30S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis and disrupting the integrity of the bacterial cell membrane. This results in a bactericidal effect against a broad spectrum of gram-negative bacteria, including *Pseudomonas aeruginosa*, *Escherichia coli*, and species of *Klebsiella*, *Enterobacter*, *Serratia*, and *Proteus*, as well as certain gram-positive bacteria such as *Staphylococcus aureus*.